| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
- Prochlorperazine
-
-
2026-06-30
- CAS:58-38-8
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 1000kg
- Prochlorperazine
-
- $1.80
-
2024-10-22
- CAS:58-38-8
- Min. Order: 1g
- Purity: 96%-99%
- Supply Ability: 1kg/10kg/100kg
- prochlorperazine
-
- $30.00
-
2024-01-18
- CAS:58-38-8
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 6000
|
| | Prochlorperazine Basic information |
| Product Name: | Prochlorperazine | | Synonyms: | 10H-Phenothiazine, 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-;2-Chloro-10-(3-(1-methyl-4-piperazinyl)-propyl)-phenothiazine;2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-10h-phenothiazin;2-chloro-10-(3-(4-methyl-1-piperazinyl)propyl)-phenothiazin;2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine;2-Chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-10H-phenothiazine;3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine;3-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine | | CAS: | 58-38-8 | | MF: | C20H24ClN3S | | MW: | 373.94 | | EINECS: | 200-379-4 | | Product Categories: | COMPAZINE;Organics | | Mol File: | 58-38-8.mol |  |
| | Prochlorperazine Chemical Properties |
| Melting point | 228 °C | | Boiling point | 260-275 °C(Press: 2 Torr) | | density | 1.1679 (rough estimate) | | refractive index | 1.6000 (estimate) | | storage temp. | Refrigerator | | solubility | Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly) | | pka | pKa 8.1(H2O,t =24±1,I undefined) (Uncertain) | | form | Solid | | color | White to Yellow | | Water Solubility | 14.96mg/L(24 ºC) | | BCS Class | 2 | | InChI | InChI=1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3 | | InChIKey | WIKYUJGCLQQFNW-UHFFFAOYSA-N | | SMILES | C1=C2C(SC3=C(N2CCCN2CCN(C)CC2)C=CC=C3)=CC=C1Cl | | CAS DataBase Reference | 58-38-8(CAS DataBase Reference) | | NIST Chemistry Reference | Prochlorperazine(58-38-8) |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral
Lact.
Repr. 2
STOT SE 3 | | Hazardous Substances Data | 58-38-8(Hazardous Substances Data) | | Toxicity | LD50 oral in rat: 1800mg/kg |
| | Prochlorperazine Usage And Synthesis |
| Uses | antiemetic, antipsychotic, treatment of vertigo | | Uses | Prochlorperazine is antiemetic, antipsychotic; used in treatment of vertigo. | | Definition | ChEBI: A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position. | | Brand name | Compazine (GlaxoSmithKline). | | Clinical Use |
Nausea and vomiting
Labyrinthine disorders
Psychoses
Severe anxiety | | Safety Profile | Poison by ingestion,
subcutaneous, intravenous, and
intraperitoneal routes. Experimental
teratogenic and reproductive effects. Human
systemic effects by ingestion: headache,
blood pressure elevation. Implicated in
aplastic anemia. When heated to
decomposition it emits very toxic fumes of
SOx, NOx, and Cl-. | | Veterinary Drugs and Treatments | Prochlorperazine as a single agent is used in dogs and cats as an antiemetic.
The only approved products for animals are combination
products containing prochlorperazine, isopropamide, with or without
neomycin (Darbazine, Neo-Darbazine—SKB Labs) which
are no longer marketed in the USA. The approved indications for
these products include: vomiting, non-specific gastroenteritis, drug
induced diarrhea, infectious diarrhea, spastic colitis, and motion
sickness in dogs and cats (injectable product only). | | Drug interactions | Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: increased risk of convulsions with
tramadol; enhanced hypotensive and sedative
effects with opioids; increased risk of ventricular
arrhythmias with methadone.
Anti-arrhythmics increased risk of ventricular
arrhythmias with anti-arrhythmics that prolong
the QT interval, e.g. procainamide, disopyramide,
dronedarone and amiodarone - avoid with
amiodarone and dronedarone.
Antibacterials: increased risk of ventricular
arrhythmias with delamanid and moxifloxacin -
avoid.
Antidepressants: increase concentrations and
additive antimuscarinic effects, notably with
tricyclics; increased risk of ventricular arrhythmias
with citalopram and escitalopram - avoid; increased
risk of convulsions with vortioxetine.
Antiepileptics: antagonised (convulsive threshold
lowered).
Antimalarials: avoid with artemether/lumefantrine
and piperaquine with artenimol.
Antipsychotics: increased risk of ventricular
arrhythmias with droperidol and pimozide - avoid;
increased risk of ventricular arrhythmias with
risperidone.
Antivirals: concentration possibly increased with
ritonavir; increased risk of ventricular arrhythmias
with saquinavir - avoid.
Anxiolytics and hypnotics: increased sedative effects.
Atomoxetine: increased risk of ventricular
arrhythmias.
Beta-blockers: enhanced hypotensive effect;
increased risk of ventricular arrhythmias with sotalol.
Cytotoxics: increased risk of ventricular arrhythmias
with arsenic trioxide.
Desferrioxamine: avoid concomitant use.
Diuretics: enhanced hypotensive effect.
Lithium: increased risk of extrapyramidal side effects
and possibly neurotoxicity.
Pentamidine: increased risk of ventricular
arrhythmias. | | Metabolism | Prochlorperazine undergoes extensive first pass
metabolism in the gut wall. It is also extensively
metabolised in the liver and is excreted in the urine and
bile. The metabolites are inactive. |
| | Prochlorperazine Preparation Products And Raw materials |
|